Pharmacogenomic biomarkers

Disease Markers

Volumn 18, Issue 2, 2002, Pages 63-71

  Kirkwood, Sandra C ^a   Hockett Jr , Richard D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Biomarkers; Pharmacogenomics

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; DEVELOPMENT; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; HUMAN; MEDICINE; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; RISK;

EID: 0036401584     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/341708     Document Type: Article

References (39)

1. A.A. Alaiya, B. Franzen, A. Hagman, C. Silfversward, B. Moberger, S. Linder and G. Auer, Classification of human ovarian tumors using multivariate data analysis of polypeptide expression patterns, Int J Cancer 86(5) (1 June 2000), 731-736.
2. A.A. Alizadeh, M.B. Eisen, R.E. Davis, C. Ma, I.S. Lossos, A. Rosenwald, J.C. Boldrick, H. Sabet, T. Tran, X. Yu, J.I. Powell, L. Yang, G.E. Marti, T. Moore, J. Jr. Hudson, L. Lu, D.B. Lewis, R. Tibshirani, G. Sherlock, W.C. Chan, T.C. Greiner, D.D. Weisenburger, J.O. Armitage, R. Warnke and L.M. Staudt et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature 403(6769) (3 Feb 2000), 503-511.
3. L.J. Baier, P.A. Permana, X. Yang, R.E. Pratley, R.L. Hanson, G.Q. Shen, D. Mott, W.C. Knowler, N.J. Cox, Y. Horikawa, N. Oda, G.I. Bell and C. Bogardus, A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance, J Clin Invest Oct 106(7) (2000), R69-73.
4. D.M. Canning and R.G. Huntsman, An assessment of Sickledex as an alternative to the sickling test, J Clin Pathol. 23(8) (Nov 1970), 736-737.
5. W. Check, CAP Today 9 (14 Sep 2000).
6. S. Cholerton, A.K. Daly and J.R. Idle, The role of individual human cytochromes P450 in drug metabolism and clinical response, Trends Pharmacol Sci. 13(12) (Dec 1992), 434-439.
7. M.A. Cobleigh, C.L. Vogel and D. Tripathy et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J Clin Oncol 17 (1999), 2639-2648.
8. F.S. Collins and V.A. McKusick, Implications of the Human Genome Project for Medical Science, JAMA 285(5) (2001), 540-544.
9. G.C. Cunningham, Phenylketonuria testing - its role in pediatrics and public health, CRC Crit Rev Clin Lab Sci. 2(1) (Jan 1971), 45-101.
10. A.K. Daly, J. Brockmoller, F. Broly, M. Eichelbaum, W.E. Evans, F.J. Gonzalez, J.D. Huang, J.R. Idle, M. Ingelman-Sundberg, T. Ishizaki, E. Jacqz-Aigrain, U.A. Meyer, D.W. Nebert, V.M. Steen, C.R. Wolf and U.M. Zanger, Nomenclature for human CYP2D6 alleles, Pharmacogenetics 6(3) (June 1996), 193-201.
11. K. Davies, Genetic screening for cystic fibrosis, Nature 357(6377) (6 June 1992), 425.
12. H.C. Dietz, G.R. Cutting, R.E. Pyeritz, C.L. Maslen, L.Y. Sakai, G.M. Corson, E.G. Puffenberger, A. Hamosh, E.J. Nanthakumar, S.M. Curristin, G. Stetten, D.A. Meyers and C.A. Francomano, Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene, Nature 352 (1991), 337-339.
13. J.M. Drazen, C.N. Yandava, L. Dube, N. Szczerback, R. Hippensteel, A. Pillari, E. Israel, N. Schork, E.S. Silverman, D.A. Katz and J. Drajesk, Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment, Nature Genetics 22(2) (June 1999), 168-170.
14. B.J. Druker and N.B. Lydon, Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia, J Clin Invest. 105 (2000), 3-7.
15. C.M. Drysdale, D.W. McGraw, C.B. Stack, J.C. Stephens, R.S. Judson, K. Nandabalan, K. Arnold, G. Ruano and S.B. Liggett, Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness, Proc Natl Acad Sci USA 97(19) (12 Sep 2000), 10483-10488.
16. J.C. Evans, T.M. Frayling, P.G. Cassell, P.J. Saker, G.A. Hitman, M. Walker, J.C. Levy, S. O'Rahilly, P.V. Rao, A.J. Bennett, E.C. Jones, S. Menzel, P. Prestwich, N. Simecek, M. Wishart, R. Dhillon, C. Fletcher, A. Millward, A. Demaine, T. Wilkin, Y. Horikawa, N.J. Cox, G.I. Bell, S. Ellard, M.I. McCarthy and A.T. Hattersley, Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom, Am J Hum Genet. 69(3) (Sep 2001), 544-552.
17. E. Gale, Lessons from the glitazones: a story of drug development, Lancet 357 (2001), 1870-1875.
18. GeneTests, http://www.genetests.org, National Institutes of Health, 2001.
19. W. Hanna, Testing for HER2 Status, Oncology 61 (Oct 2001), S2:22-30.
20. W.E. Highsmith Jr, G.L. Chong, H.T. Orr, T.R. Perry, D. Schald, R. Farber, K. Wagner, M.R. Knowles, W.J. Warwick and L.M. Silverman et al., Frequency of the delta Phe508 mutation and correlation with XV.2c/KM-19 haplotypes in an American population of cystic fibrosis patients: results of a collaborative study, Clin Chem 36(10) (Oct 1990), 1741-1746.
21. Y. Horikawa, N. Oda, N.J. Cox, X. Li, M. Orho-Melander, M. Hara, Y. Hinokio, T. Linder, H. Mashima, P. Scwarz, L. del Bosque-Plata, Y. Horikawa, Y. Oda, I. Yoshiuchi, S. Colilla, K. Polonsky, S. Wei, P. Concannon, N. Iwaski, J. Schulze, L. Baier, C. Bogardus, L. Groop, E. Boerwinkle, C. Hanis and G. Bell, Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus, Nature Genet 29 (2000), 163-175.
22. Huntington Disease Collaborative Research Group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes, Cell 72(6) (26 March 1993), 971-983.
23. M. Kalidas, H. Kantarjian and M. Talpaz, Chronic myelogenous leukemia, JAMA 286(8) (22-29 Aug 2001), 895-898.
24. H. Kantarjian, C. Sawyers, A. Hochhaus, F. Guilhot, C. Schiffer, C. Gambacorti-Passerini, D. Niederwieser, D. Resta, R. Capdeville, U. Zoellner, M. Talpaz, B. Druker and The International STI571 CML Study Group, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia, N Engl J Med. 346(9) (28 Feb 2002), 645-652.
25. S. Kaptain, L.K. Tan and B. Chen, Her-2/neu and breast cancer, Diagn Mol Pathol 10(3) (Sep 1990), 139-152.
26. J. Khan, J.S. Wei, M. Ringner, L.H. Saal, M. Ladanyi, F. Westermann, F. Berthold, M. Schwab, C.R. Antonescu, C. Peterson and P.S. Meltzer, Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks, Nat Med. 7(6) (June 2001), 673-679.
27. K.W. Kinzler, M.C. Nilbert, L.K. Su, B. Vogelstein, T.M. Bryan, D.B. Levy, K.J. Smith, A.C. Preisinger, P. Hedge and D. McKechnie et al., Identification of FAP locus genes from chromosome 5q21, Science 253(5020) (9 Aug 1991), 661-665.
28. E.S. Lander, L.M. Linton, B. Birren and C. Nusbaum, Initial sequencing and analysis of the human genome, Nature 409(6822) (2001), 860-921.
29. C. Lengauer, K.W. Kinzler and B. Vogelstein, Genetic instabilities in human cancers, Nature 396(6712) (17 Dec 1998), 643-649.
30. K.R. Merikangas and J.D. Swendsen, Genetic Epidemiology of psychiatric disorders, Epidemiolo Rev 19 (1997), 144-155.
31. No author, The human genome. Science genome map, Science 291(5507) (2001), 1218.
32. N. Risch and K. Merikangas, The future of genetics of complex diseases, Science 273 (1996), 1516-1517.
33. M.A. Rothstein, Genetic Secrets: Protecting Privacy and confidentiality in the Genetic Era. Yale University Press. New Haven, Connecticut, 1997.
34. V.P. Shah, A. Yacobi, W.H. Barr, L.Z. Benet, D. Breimer, M.R. Dobrinska, L. Endrenyi, W. Fairweather, W. Gillespie, M.A. Gonzalez, J. Hooper, A. Jackson, L.J. Lesko, K.K. Midha, P.K. Noonan, R. Patnaik and R.L. Williams, Evaluation of orally administered highly variable drugs and drug formulations, Pharm Res. 13(11) (Nov 1996), 1590-1594.
35. T. Sorlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, T. Thorsen, H. Quist, J.C. Matese, P.O. Brown, D. Botstein, P. Eystein Lonning and A.L. Borresen-Dale, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci USA 98(19) (11 Sep 2001), 10869-10874.
36. M. Spatzenegger and W. Jaeger, Clinical importance of hepatic cytochrome P450 in drug metabolism, Drug Metab Rev. 27(3) (1995), 397-417.
37. D.S. Streetman, J.S. Jr. Bertino and A.N. Nafziger, Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes, Pharmacogenetics 10(3) (April 2000), 187-216.
38. B.S. Wilfond, Screening policy for cystic fibrosis: the role of evidence, Hastings Cent Rep. 25(3) (May-Jun 1995), S21-23.
39. C. Wright, K. Prasad and T.J. Lennard, ErbB2 expression in breast and other human tumors, J Clin Pathol. 45(5) (May 1992), 459-460.